AstraZeneca and Daiichi Sankyo disclosed data showing Enhertu has benefit when given earlier in breast cancer, supporting the drug’s move into potentially curative settings. Presentations at ESMO reported improvements in outcomes for patients treated with Enhertu in pre‑surgical or early‑stage disease cohorts, prompting companies and clinicians to consider expanding indications. Separately, commentary at the meeting highlighted the broader trend of ADCs being tested earlier in disease as manufacturers seek curative opportunities.